Anbio Biotechnology is devoted to making contributions to human health and has never stopped our goal to innovate in life sciences. Driven by continuous technical development and integration, resulting from close cooperation with prestigious institutes across the world. Anbio always strives to provide total solutions in the clinical diagnosis field, by offering extensive diagnostic products including laboratory and point-of-care products.
Our mission is to change the global diagnostics market by individualizing and decentralizing the current diagnostic solutions for rapid diagnosis to improve patient prognosis.
WBM: What is Anbio Biotechnology's mission?
ML: Anbio Biotechnology is a global developer and medical device distributor specializing in in vitro diagnostics products. Our mission is to change the global diagnostics market by individualizing and decentralizing the current diagnostic solutions for rapid diagnosis to improve patient prognosis.
Our products cover mature laboratory diagnostics, point-of-care technology (“POCT”), and molecular diagnostics instruments and reagents, which can detect infectious diseases, cancer, cardio, diabetes etc. We provide a mature portfolio for each sector, with various tests to diagnose abnormalities in individuals, compatible with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva.
WBM: What milestones can we look forward to from Anbio Biotechnology in the near future?
ML: Anbio Biotechnology is working on expand global market, strive to provide high-quality clinical laboratory and point-of-care diagnostic products accessible to all, where our mission is to change the global diagnostics market by individualizing and decentralizing the current diagnostic solutions for rapid diagnosis to improve patient prognosis.
WBM: Your background is biochemistry and molecular biology. How does this influence your role as CEO?
ML: With a biochemistry and molecular biology background, having the scientific foundation and understanding of the mechanistic underpinnings of each platform that we provide for our clients is extremely important. Having this foundational understanding allows for me to decide not only based on business principles but also on my scientific understanding.
WBM: How have you approached building your team at Anbio Biotechnology and what have you learned from this journey?
ML: Team building has been interesting and challenging. With my experience, I understand the organizational structure required for a successful business, but identifying the right talent, especially in leadership positions, has been challenging. Hence, Anbio is still building, hiring, and identifying the right talent to take the company to the next level. The biggest takeaway from this experience is the importance of patience to find the right individual, not perfect, but the right people to fill the vacancies.
"Great leadership is to put the good of the talent and the company before your own interests. Leadership is not to be barking orders at employees; rather, it is important to set a platform for success and allow for the individual to develop a system of their own to succeed and thrive, not only in the current position but for future success as well."
WBM: In your opinion, what qualities are required for great leadership?
ML: Great leadership is to put the good of the talent and the company before your own interests. Leadership is not to be barking orders at employees; rather, it is important to set a platform for success and allow for the individual to develop a system of their own to succeed and thrive, not only in the current position but for future success as well. Additionally, a leader needs to support as needed, hold individuals accountable, clearly define goals, and provide flexibility to ensure an individual can develop, learn, and improve daily. Lastly, a leader must be empathetic to view all employees as human beings with intangibles rather than a number on the P&L statement.
WBM: How is AI being used in your field?
ML: AI can help design critical components in IVD products, including the molecular design of antibodies, primers, and other molecular components that can improve the efficacy of diagnostic assays to improve prognosis.
WBM: ESG is often an afterthought for young companies. How do you ensure this isn't the case at Anbio?
ML: ESG is certainly not an afterthought for Anbio. We consistently remind our employees to understand and implement ESG principles. At Anbio, we believe it's essential for our companies to incorporate ESG principles into our operations to align with sustainability and responsible business practices, gain the trust of stakeholders, and remain competitive in an ESG-conscious world.
WBM: Tell us about innovation at Anbio.
ML: At Anbio, we hire ambitious, science-driven, curious individuals who understand innovation is the key to our success. Innovation will always be the priority for Anbio to ensure that we don’t fall behind the ever-moving healthcare market.
WBM: How do you maintain high levels of self motivation?
ML: My motivation in my career and life is to have fun, learn every day, and be excited to do my part in the progression for a better quality of life for all, today and for the future.